biospecimen banks

CPDR Patient Education Program

Industry-Sponsored Clinical Trials and Projects

The CRC maintains a comprehensive portfolio of both investigator-initiated and industry sponsored clinical trials that cover the entire patient's "life cycle." Some of the trials, though industry sponsored, are investigator-initiated trials for which a proposal was submitted by CPDR to obtain funding. All trials and projects are carried out with full approval of the respective IRBs.

 

CPDR Open Clinical Trials


  1. ProstAtak Trial

    A randomized trial of ProstAtak in combination with standard external beam radiation therapy with or without androgen deprivation therapy is in men with intermediate to high risk localized prostate cancer. ProstAtak is an investigational product that is meant to kill tumor cells and elicit an anti-tumor vaccine effect. In a Phase II clinical trial of ProstAtak given with radiation, prostate cancer recurrence was three-fold lower than typically seen with radiation alone. The purpose of this Phase III trial is to definitively determine if ProstAtak reduces prostate cancer recurrence

     

  2. BAYER - RADIUM 223

    A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride (radium 223 dichloride is FDA approved drug that targets prostate cancer in the bones), in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer

     

  3. AMOR3-SV

    A phase 3, randomized, open-label, multi-center, controlled study of Galeterone compared to Enzalutamide in men expressing androgen receptor splice variant-7 mRNA (AR-V7) with metastatic (M1) castrate resistant prostate cancer (CRPC). Galeterone is a selective, multi-targeted, small molecule drug for the treatment of castrate resistant prostate cancer

     

CONTACT Information: Judith A. Travis, RN, Walter Reed National Military Medical Center, Center for Prostate Disease Research, America Building 19, Room 3225 on the 3rd floor.
301-319-2927 or Judith.a.travis.ctr@mail.mil

CURRENT EVENTS


May 13, 2016

CPDR Student Participant Wins The AACR Gary J. Miller Undergraduate Prize for Cancer and Cancer Related Biomedical Research

A third place prize in the AACR Undergraduate Student Caucus and Poster Competition was awarded to Ms. Shahnoza Dusmatova, a CPDR participant in the DoD "Research and Education Program for Historically Black Colleges and Universities and Minority-Serving Institutions (HBCU/MI)".

Read Full Article

 

May 2, 2016

CPDR Presentations and Highlights at the 2016 AACR Annual Meeting in New Orleans, La.

The Center for Prostate Disease Team has presented their new findings in prostate cancer research at the American Association for Cancer Research Annual Meeting 2016 in New Orleans, Louisiana, USA.

The Team led by Dr. David G. McLeod, Director and Dr. Shiv Srivastava, Co-Director presented the ground breaking discovery of the first recurrent cancer genomic defect of prostate cancers of African American men revealed by whole genome sequencing. The title of the poster presentation was “LSAMP gene deletion is associated with rapid disease progression in prostate cancer of African American men”.

Read Full Article

 

February 2, 2016

CPDR Urology Residents Take Top Awards at 2016 James C. Kimbrough Urological Seminar

Urology Residents conducting research at The Center for Prostate Disease Research (CPDR), Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center presented their research at the Residents Competition category of the James C. Kimbrough Urological Seminar, San Diego, 2016.

Read Full Article

 

WRNMMC UsToo!


and the MAY 2016 WRNMMC UsToo! Newsletter

or go to theWRNMMC UsToo! Newsletter Archive

Read the MAY 2016 CPDR E-Newsletter